PAX5 and precursor B-cell acute lymphoblastic leukemia: Previous studies revealed that as a B-lymphoid transcription factor, PAX5 was downregulated in over 80% of pre-B cell acute lymphoblastic leukaemia (ALL), and its downregulation in lymphoid neoplasms was associated with promoter hypermethylation and poor clinical outcomes [37, 38].